Nalfurafine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nalfurafine
Nalfurafine.svg
Systematic (IUPAC) name
(2E)-N-[(5α,6β)-17-(cyclopropylmethyl)- 3,14-dihydroxy- 4,5-epoxymorphinan- 6-yl]- 3-(3-furyl)- N-methylacrylamide
Clinical data
AHFS/Drugs.com International Drug Names
intravenous
Identifiers
152658-17-8 YesY
V03AX02
PubChem CID 6445230
IUPHAR ligand 1651
ChemSpider 4949003 N
UNII XC41AVD567 YesY
ChEMBL CHEMBL267495 N
Synonyms TRK-820
Chemical data
Formula C28H32N2O5
476.564 g/mol
 N (what is this?)  (verify)

Nalfurafine (INN and USAN;[1] also known as AC-820, TRK-820; trade name Remitch) is a κ-opioid receptor agonist marketed as a treatment for uremic pruritus in people undergoing hemodialysis.[2]

As of January 2010, it is also being investigated for the treatment of pruritus in patients with chronic liver disease.[3]

References[edit]

  1. ^ Statement on a Nonproprietary Name adopted by the USAN Council
  2. ^ "AC-820". Acologix. 2009. 
  3. ^ Clinical trial number NCT00638495 for "Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease" at ClinicalTrials.gov